Abcellera Biologics is trading 30.88% up now at $9.07 after announcing positive top-line Phase 2 data for ABCL635, a treatment for moderate-to-severe menopause-related vasomotor symptoms. The study met its primary efficacy endpoints, demonstrating statistically significant reductions in both frequency and severity of symptoms. Management had previously reported that enrollment for the trial was completed ahead of schedule.